Stocktoria
Relay Therapeutics, Inc. RLAY
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-07-16
Chart by TradingView
3/9
Piotroski F — financial health
2.96
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M |
| Operating income | -$302.7M | -$372.5M | -$373.0M | -$299.3M | -$364.7M |
| Net income | -$276.5M | -$337.7M | -$342.0M | -$290.5M | -$363.9M |
| Operating cash flow | -$235.5M | -$249.1M | -$300.3M | -$229.5M | -$74.4M |
| Free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M | -$77.9M |
| Total assets | $621.3M | $871.3M | $844.0M | $1.1B | $1.0B |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M | $110.6M |
| Shareholders' equity | $567.1M | $777.8M | $752.0M | $950.2M | $897.8M |
| Ratios | |||||
| Operating margin | -1971.6% | -3722.1% | -1460.1% | -21670.9% | -12040.2% |
| Net margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% |
| FCF margin | -1536.1% | -2509.5% | -1191.7% | -17273.9% | -2571.0% |
| Return on assets | -44.5% | -38.8% | -40.5% | -26.4% | -36.1% |
| Return on equity | -48.8% | -43.4% | -45.5% | -30.6% | -40.5% |
| Current ratio | 22.61 | 15.95 | 25.44 | 16.00 | 40.14 |
| Revenue growth | 53.4% | -60.8% | 1749.8% | -54.4% | -96.3% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 673,599 | $6.7M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.96 (safe)
- Working capital / assets 0.89
- Retained earnings / assets -3.243
- EBIT / assets -0.487
- Equity / liabilities 10.449
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001812364 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.